XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly RMB 100 million (USD 14 million) in a Series A financing round. The round was led by Legend Capital, with participation from existing investors TIgerYeah Capital, Proxima Ventures, Dalton Venture, and Tao Capital. The funds raised will be directed towards regulatory filings, clinical trials, and the expansion of the company’s product pipeline.
Founded in 2020, XRGenesis has an impressive portfolio of ophthalmic devices, including cataract phacoemulsification devices, a vitrectomy surgery system, ultrasonic and laser glass cutting systems, and endoscopic OCT, among others.- Flcube.com
